Abstract-We described recently that systemic hypoxia provokes vasoconstriction in heart failure (HF) patients. We hypothesized that either the exaggerated muscle sympathetic nerve activity and/or endothelial dysfunction mediate the blunted vasodilatation during hypoxia in HF patients. Twenty-seven HF patients and 23 age-matched controls were studied. Muscle sympathetic nerve activity was assessed by microneurography and forearm blood flow (FBF) by venous occlusion plethysmography. Peripheral chemoreflex control was evaluated through the inhaling of a hypoxic gas mixture (10% O 2 and 90% N 2 ). Basal muscle sympathetic nerve activity was greater and basal FBF was lower in HF patients versus controls. During hypoxia, muscle sympathetic nerve activity responses were greater in HF patients, and forearm vasodilatation in HF was blunted versus controls. Phentolamine increased FBF responses in both groups, but the increase was lower in HF patients. Phentolamine and N G -monomethyl-L-arginine infusion did not change FBF responses in HF but markedly blunted the vasodilatation in controls. FBF responses to hypoxia in the presence of vitamin C were unchanged and remained lower in HF patients versus controls. In conclusion, muscle vasoconstriction in response to hypoxia in HF patients is attributed to exaggerated reflex sympathetic nerve activation and blunted endothelial function (NO activity). We were unable to identify a role for oxidative stress in these studies. (Hypertension. 2012;60:669-676.) • Online Data Supplement Key Words: heart failure � chemoreceptors � vasodilation � sympathetic nervous system � endothelium R esting sympathetic nerve activity is increased in patients with chronic systolic heart failure (HF), and patients with the greatest sympathetic activation have the highest mortality.
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decreased NO availability in HF and thereby contributes to the impaired vasodilatation during hypoxia in HF.
Methods Population
Twenty-seven advanced HF patients (mean age, 45Ϯ2 years) and 23 healthy normal controls (mean age, 40Ϯ2 years) participated in the study. All of the HF patients were in New York Heart Association, Functional Class III, and had idiopathic dilated cardiomyopathy and ejection fraction Ͻ40%. Twenty-five patients were using ␤-blocker therapy, 27 angiotensin-converting enzyme inhibitor, and 23 diuretic, 3 antiarrhythmic, and 15 calcium blocker. Exclusion criteria were as follows: (1) myocardial infarction within 3 months; (2) unstable angina; (3) pacemaker; (4) peripheral neuropathy; (5) diabetes mellitus; and (6) obesity (or body mass index Ͻ30 kg/m 2 ). The study was approved by the human subject protection committee of the Heart Institute (InCor) and Clinical Hospital, University of São Paulo, Medical School, and the participants gave their written informed consent.
Procedures and Measures
Muscle Sympathetic Nerve Activity
Muscle sympathetic nerve activity (MSNA) was directly measured from the peroneal nerve using the technique of microneurography. A detailed description of the MSNA method is available in the online-only Data Supplement.
Forearm Blood Flow
Forearm blood flow (FBF) was measured by the noninvasive technique of venous occlusion plethysmography. A detailed description of the FBF method is available in the online-only Data Supplement.
Chemoreflex Control
Peripheral chemoreflex control was evaluated through the inhaling of a hypoxic gas mixture (10% O 2 and 90% N 2 ), for a 3-minute period, as described previously. 8, 9 In the stimulation of peripheral chemoreceptors during hypoxia, the influence of central chemoreceptors was minimized by the maintenance of isocapnia, with titrated carbon dioxide. 6 
Arterial Catheterization
After aseptic technique and subsequently local anesthesia (1% lidocaine) in the nondominant arm, a 5-cm catheter was placed in the brachial artery. The catheter was connected to a pressure transducer and flushed continuously at 3 mL/h with saline containing 2 U of heparin per milliliter. A 3-port connector was placed in series with the catheter-transducer system. One port was used to monitor arterial pressure and the other port for drug infusion.
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Drug Preparation and Infusions
Saline (NaCl, 0.09%) was infused into the brachial artery and used as a control for drug sequence. The ␣-adrenergic blockade phentolamine (Regitine, Ciba Pharmaceutical, Summit, NJ) was formulated at a specific concentration using sterile normal saline and infused into the brachial artery at a dose of 100 m/min, as described previously. [11] [12] [13] The N G -monomethyl-L-arginine (L-NMMA; Clinalfa, Laufelfingen, Switzerland) was formulated at a specific concentration using sterile normal saline and infused into the brachial artery at a dose of 4 mg/min, as described previously. 14, 15 The vitamin C was infused into the brachial artery at a dose of 25 mg/min, a dose that has been shown previously to improve endothelial dysfunction in HF. 16 
Experimental Protocols
Protocol 1
See Figure 1 . The purposes of this study were to determine whether sympathetic nerve activity significantly restrained muscle blood flow response during hypoxia in patients with HF and whether, in the present of sympathetic blockade and/or impaired NO-mediated vasodilation, it contributed to the paradoxical vasoconstriction in HF during hypoxia. Thirteen patients with advanced HF and 13 normal healthy controls participated in the study after fasting for Ն3 hours and abstaining from caffeine for 24 hours. All of the subjects were studied at approximately the same time of day. Medications were held for 12 hours before instrumentation. The subject was positioned, and an intra-arterial catheter was placed into the brachial arterial of the nondominant arm. Cuffs for FBF measurements were placed on the same arm. The catheter was attached to a 3-way stopcock for ease of intra-arterial drug infusion. After a 15-minute rest period, saline was infused (0.5 mL/min) for 5 minutes, and baseline values for FBF, arterial pressure, heart rate, and MSNA were recorded for 3 minutes. Then, hypoxia was conducted for 3 minutes. After a 15-minute rest period in normoxia, a 5-minute period of intraarterial infusion of phentolamine (␣ 1 -adrenergic blockade antagonist, 100 g/min) was conducted. 11 New baseline FBF, arterial pressure, heart rate, and MSNA were recorded for 3 minutes, followed by a 3-minute period of hypoxia with phentolamine infusion. Finally, after a 15-minute rest period, a 5-minute period of intra-arterial infusion of phentolamine associated with L-NMMA (Clinalfa, 4 mg/min) was conducted. 12, 13 Then, new baseline FBF, arterial pressure, heart rate, and MSNA were recorded for 3 minutes, followed by a 3-minute period of hypoxia with phentolamine and L-NMMA infusion. Saline and drugs were infused continuously at rate of 0.5 mL/min.
Protocol 2
See Figure 1 . The purposes of this study were to determine whether reduction of oxidative stress would improve muscle blood flood response during hypoxia in patients with HF and whether, in the presence of antioxidant vitamin C, sympathetic nerve activation during hypoxia continued to contribute to the paradoxical vasoconstriction during hypoxia in HF. Fourteen patients with advanced HF and 10 healthy controls participated in the study. After preparation and instrumentation as in protocol 1, a 15-minute rest period was allowed. Then, saline was infused (0.5 mL/min) for 5 minutes. Baseline values for FBF, arterial pressure, heart rate, and MSNA were recorded for 3 minutes. Then, hypoxia was conducted for 3 minutes. After a 15-minute rest period, vitamin C (25 mg/min) was infused for 5 minutes. New baseline FBF, arterial pressure, heart rate, and MSNA were recorded for 3 minutes, followed by a 3-minute period of hypoxia with vitamin C infusion. Finally, after a 15-minute of rest period, vitamin C associated with phentolamine was infused for 5 minutes. New baseline of FBF, arterial pressure, heart rate, and MSNA were recorded for 3 minutes. Then, new baseline FBF, arterial pressure, heart rate, and MSNA were recorded for 3 minutes, followed by a 3-minute period of hypoxia with vitamin C and phentolamine infusion. Saline and drugs were infused continuously at a rate of 0.5 mL/min.
Statistical Analysis
The data are presented as meanϮSE. The similarity in physical characteristics between the groups was tested by use of an unpaired t test. The responses of heart rate, mean blood pressure, FBF, forearm vascular conductance (FVC), pulmonary ventilation, O 2 saturation, end-tidal CO 2 , and MSNA were analyzed by 2-way ANOVA with repeated measures. When significance was observed, post hoc Scheffé was used to test the difference between conditions. 2 test was used to evaluate the sex proportion between groups. P values of PϽ0.05 were considered statistically significant.
Results
Basal Measurements
Basal characteristics in normal controls and HF patients are shown in Table 1 . Hemodynamic and neural basal levels are shown in Table 2 . Resting MSNA was greater and resting FBF was lower in HF patients compared with healthy controls. Blood pressure was also lower in HF patients.
Neurovascular Responses During Chemoreceptor Stimulation With Saline Control
Hemodynamic and respiratory responses in HF patients and healthy controls during saline control infusion, normoxia, and hypoxia are displayed on Table S1 (available in the onlineonly Data Supplement) and Figure 3 . Hypoxia provoked a greater increase in MSNA in HF patients versus healthy controls (interaction, Pϭ0.02; Figure 2 ). In healthy controls, during hypoxia, FBF increased compared with basal levels. In contrast, FBF responses to hypoxia in HF patients did not change. Thus, FBF responses to hypoxia were significantly lower in HF patients compared with healthy controls (interaction, Pϭ0.002; Figure 3A) . Similarly, FVC responses to hypoxia were significantly lower in HF patients compared with controls (interaction, Pϭ0.002; Figure 3D ).
Neurovascular Responses During Hypoxia With Phentolamine and/or L-NMMA Infusion
Phentolamine Hemodynamic and respiratory responses in HF patients and healthy controls during phentolamine infusion, which blocks ␣-adrenergic receptors, during normoxia and hypoxia, are displayed in Table S1 and Figure 3 . MSNA responses to hypoxia in the presence of phentolamine infusion remained significantly greater in HF patients compared with healthy controls. In healthy controls, FBF responses to hypoxia were significantly increased in the presence of phentolamine compared with saline control. Similarly, in HF patients, FBF responses during hypoxia were significantly increased in the presence of phentolamine compared with saline control, consistent with the notion that sympathetic nerve activity restrains vasodilation during hypoxia in both groups, but this effect is augmented in HF patients, in whom MSNA responses to hypoxia are exaggerated. Nonetheless, comparison between groups showed that FBF remained lower in HF patients compared with controls (group, Pϭ0.055; Figure  3B ). In the presence of phentolamine, hypoxia significantly increased FVC responses in HF patients and controls. The comparison between groups showed that FVC responses were not different in HF patients and controls (group, Pϭ0.08; Figure 3E ). Values are meanϮSE. NC indicates normal control; HF, heart failure; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; FBF, forearm blood flow; FVC, forearm vascular conductance; MSNA, muscle sympathetic nerve activity. 
Phentolamine and L-NMMA
Hemodynamic and respiratory responses during infusion of phentolamine and L-NMMA, which blocks NO production, during normoxia and hypoxia, are displayed in Table S1 and Figures 3 and 4 . MSNA responses to hypoxia during phentolamine and L-NMMA infusion remained greater in HF patients versus controls. In healthy controls during phentolamine and L-NMMA infusion, the increase in FBF during hypoxia was blocked by L-NMMA, consistent with the concept that NO mediated the vasodilation during hypoxia in controls ( Figure 3C ). In HF patients, the addition of L-NMMA to phentolamine did not alter the FBF responses to hypoxia compared with phentolamine alone, consistent with the concept that endothelial-mediated vasodilation has little influence in the FBF responses during hypoxia in HF patients ( Figure 3C ). Similar findings were observed in FVC ( Figure 3F ).
Neurovascular Responses During Hypoxia With Vitamin C and Phentolamine Infusion
Vitamin C (Antioxidant) and Phentolamine Infusion Hemodynamic and respiratory responses to vitamin C infusion, an antioxidant, during normoxia and hypoxia are displayed in Table S2 and Figure 4 and 5. Vitamin C infusion during normoxia did not significantly change FBF and FVC responses in healthy controls or HF patients ( Figure 4C and 4D). Vitamin C and phentolamine infusion significantly increased FBF and FVC responses during hypoxia in HF patients ( Figure 5C and 5F, respectively). The increase in muscle blood flow was so pronounced that the differences in FBF responses between groups were only observed at the range of 85% to 80% O 2 saturation ( Figure 5C ). In the presence of vitamin C and phentolamine, no significant differences in FVC responses were found between groups (group, Pϭ0.37; Figure 5F ).
Discussion
The present study was conducted to investigate whether the exaggerated sympathetic outflow explained the blunted muscle vasodilatory response to hypoxia in patients with chronic HF. We found that, in the presence of postsynaptic ␣-adrenergic receptors, blockade with phentolamine FBF significantly increased in response to hypoxia in HF patients. However, the vasodilatation remained significantly less compared with healthy humans during hypoxia. We conclude that the greater blood flow during hypoxia in healthy humans compared with HF patients is attributable to endothelium-mediated vasodilatation, because L-NMMA infusion during hypoxia eliminated this augmented FBF in healthy humans. As reported previously, 9, [17] [18] [19] chemoreceptor stimulation by systemic hypoxia provokes increases in sympathetic nerve activity. Our study is consistent with these previous studies. In addition, our findings support the concept that, in addition to augmented sympathetic nerve activity, decreased NO release from the endothelium contributes to the blunted muscle vasodilation during hypoxia in HF patients.
Vitamin C provides protection against oxidative stress. Vitamin C protects cellular damage by scavenging reactive oxygen species. 20 In addition, vitamin C recycles the endothelial NO synthase cofactor tetrahydrobiopterin, which increases endothelial NO synthase function 19 and, in consequence, NO bioavailability. Vitamin C has an important role in influencing vascular function. Based on this knowledge and previous studies in which vitamin C increased flow-dependent endothelial-mediated vasodilation in HF patients, 21 we reasoned that vitamin C would similarly improve muscle vascular responses during hypoxia in patients with HF. Surprisingly, infusion of vitamin C had no detectable effect on FBF during normoxia or hypoxia either in healthy humans or HF patients. Potential explanations are that the sympathetic outflow provoked by hypoxia in HF overwhelmed the endothelium-mediated vasodilatation even in the absence of oxidative stress or the vitamin C dose was insufficient to restore endotheliummediated vasodilatation during systemic hypoxia in HF patients. The dose used, however, was based on previous studies in humans with HF, in whom endotheliummediated vasodilatation was significantly improved after vitamin C infusion. 21 The blunted vasodilatation mediated by combination of augmented sympathetic outflow and impaired endothelial function in response to hypoxia in HF has important clinical implications. This abnormal response to systemic hypoxia predisposes to hypoperfusion and worsening hypoxemia in muscle, and potentially other tissues as well, in patients with HF. Coronary vasoconstriction substantially enhances the cardiovascular risk in patients with chronic HF, especially those with ischemic etiology. 22 Periodic breathing and central or obstructive sleep apnea frequently experienced by many HF patients result in hypoxia, 23 thereby leading to significantly increased sympathetic nerve activity. 23 The resulting vasoconstriction is not likely offset by local muscle vasodilatation. This dual response may contribute to a pathophysiological downward spiral of sympathetic activation, vasoconstriction, and increased mortality in patients with HF.
Our study provides insights into the mechanisms underlying this abnormal response to hypoxia and may lead to strategies to improve vascular function in response to hypoxia in HF patients. We tested the concept that the antioxidant vitamin C, which augments NO, might restore compensatory muscle vasodilation during hypoxia in patients with chronic HF. Unfortunately, vitamin C had no detectable effect.
The present study provides others interesting information regarding autonomic control in HF patients. Patients with HF were hyperventilating at rest, resulting in low CO 2 values. The stimulus to this hyperventilation in chronic, , vitamin C, and vitamin Cϩphentolamine infusion in heart failure patients and healthy controls. Note that, in both healthy controls and heart failure patients, phentolamine, phentolamineϩL-NMMA, and vitamin Cϩphentolamine infusion significantly increase FBF and FVC, but vitamin C alone has no effect. The addition of L-NMMA to phentolamine significantly decreases FBF at rest in both groups, consistent with vasodilatory effect of NO during normoxia. *Betweengroup difference, PϽ0.05; †within-group difference, PϽ0.05; ‡phentolamine vs phentolamineϩL-NMMA, PϽ0.05; §vitamin C vs vitamin Cϩphentolamine.
compensated HF remains unknown. Despite increased minute ventilation in HF patients at rest, the ventilator responses to hypoxia were not different between HF patients and normal controls. These findings are consistent with our previous study 6 in which similar ventilatory responses to hypoxia in chronic HF patients and normal controls were found. Perhaps one explanation is the unequal baseline respiratory rates, because HF patients were hyperventilating at rest, and, thus, the potential, further increase in respiratory rate in response to hypoxia was less compared with controls. Augmented peripheral chemoreflex control of sympathetic nerve activity during hypoxia has been documented in pacing-induced HF in rabbits 24 and humans with HF. 6, 25 More recently, other investigators reported that increased chemoreflex sensitivity decreases baroreflex control of sympathetic nerve activity in chronic HF patients, 26 which may explain the role of the chemoreflex sensitivity in the adverse prognosis in ambulatory patients with chronic HF. 27 The novel finding in the present study is the increased peripheral chemoreflex control of MSNA even in very mild change in oxygen saturation (Figure 2 ).
Limitations
We recognize several limitations in our study. First, we cannot rule out the possibility that the vasoconstriction during hypoxia in HF patients is restricted to skeletal muscle, because blood flow was only measured in the forearm. Second, muscle vasodilatation provoked by systemic hypoxia is a complex process that involves multiple redundant mechanisms. [28] [29] [30] [31] Although we only studied NO, other vasodilator mechanisms may have been impaired as well. This seems unlikely, however, because L-NMMA administration completely abolished the augmented FBF response during hypoxia in healthy humans during phentolamine infusion. These findings are in line with previous studies that show the importance of NO in the muscle vasodilation during systemic hypoxia and hypoperfusion. 28 Third, venous occlusion plethysmography does not allow us to separate muscle blood flow from skin blood flow. Fourth, although there were no significant differences in oxygen saturation between HF and healthy controls, there is no guarantee that the experimental conditions were equal between groups. Similarly, the comparable end-tidal CO 2 does not necessarily mean that the isocapnic condition during experimental protocols was equal between groups. The chronic differences in end-tidal CO 2 between HF patients and healthy controls may not be equalized simply by acutely raising end-tidal CO 2 in HF patients, because this will acutely alter the acid-base status. Fifth, we cannot rule out that the treatment with medications, including carvedilol, influenced our results. We were dealing with very sick patients. Thus, for safety and ethical reasons, medications were discontinued for 12 hours. Thus, it is possible that the medications remained active during our experiments. Partially attributable to carvedilol, HR increased less in response to hypoxia in HF patients than in normal controls, which may raise the possibility that the blunted vasodilatory responses in HF patients are because of lower cardiac output. The vasodilatory effects of carvedilol and other medications might restrain the rise in blood pressure during hypoxia in the patients with HF, despite greater vasoconstrictor forces in these patients. On the other hand, the similarity in blood pressure lessens the likelihood that the difference in vasodilatory responses between HF patients and normal controls was attributed to perfusion pressure. Sixth, our study provides no tests on the effectiveness of pharmacological blockade/ inhibition during drug infusion (eg, phentolamine, L-NMMA, or vitamin C). Finally, we can only exclude that a brief exposure to 1 dose of vitamin C had no effect on muscle vasodilatation during hypoxia. It is possible that a greater exposure to vitamin C or another, more potent, antioxidant may have had a measurable effect on muscle blood flow.
Perspectives
HF is characterized by a constellation of physiological alterations. In this study, we demonstrate that hypoxia provokes exaggerated sympathetic nerve discharge in HF patients. In addition, this abnormal autonomic control has vascular implications, because the muscle vasoconstriction during hypoxia in HF patients is, in great part, mediated by sympathetic nerve activity. These findings extend our knowledge regarding the mechanisms underlying the vascular dysfunction in HF. Moreover, they point to the fact that the reduction in sympathetic nerve activity must be one of the main targets in the treatment of vascular dysfunction in HF patients.
In conclusion, the present study shows that the paradoxical muscle vasoconstriction in response to hypoxia in HF patients is attributed to exaggerated reflex sympathetic nerve activity and impaired endothelium function. A role for the oxidative stress, which, in turn, reduces the NO bioavailability, was not demonstrated in these studies. 
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Procedures and Measures
Muscle Sympathetic Nerve Activity. MSNA was directly measured through a multiunit recording of the postganglionic efferent nerve from the nervous muscle fascicle, on the posterior side of the peroneal nerve, immediately inferior to the fibular head.
1 Multiunit post-ganglionic muscle sympathetic nerve recordings were made using a tungsten microelectrode. Signals were amplified by a factor of 50,000-100,000 and band-passed filtered (700-2,000 Hz). Nerve activity was rectified and integrated (time constant 0.1 s) to obtain a mean voltage display of sympathetic nerve activity that was recorded on paper 2 . All recordings of MSNA met previously established and described criteria. 1 Muscle sympathetic bursts were identified by visual inspection by a single investigator (CEN) blinded to the study protocol, and were expressed as burst frequency (bursts per minute) and burst incidence (bursts per 100 heart beats). The reproducibility of MSNA has been previously reported.
1 Forearm Blood Flow. Forearm blood flow (FBF) was measured by the noninvasive technique of venous occlusion plethysmography. 3 The resting nondominant arm was elevated above the right atrium to ensure adequate venous drainage. A mercury-filled Silastic tube attached to a low-pressure transducer was placed around the forearm, 5 cm distant from the humero-radial joint, and connected to a plethysmography device (Hokanson 201 AG). Sphygmomanometer cuffs were placed around the wrist and the upper arm. One minute before the measurements were taken, the wrist cuff was inflated at a level above the systolic blood pressure level. At 15-s intervals, the upper cuff was inflated above venous pressure for 7-8s. The increase in the tension in the Silastic tube reflects the increase in the forearm volume and, consequently, the vasodilation. The wave signal of the FBF was captured in a computer through Windaq program, at a 500-Hz frequency. Forearm vascular conductance (FVC) was calculated by dividing FBF (ml . min -1.
100 ml -1 ) by mean arterial pressure (mmHg) and expressed in units.
Supplemental Tables   Table S1 . Hemodynamic and respiratory responses during hypoxia with phentolamine and L-NMMA infusion in normal controls and heart failure patients. Values are means ± SE. NC, normal control; HF, heart failure; HR, heart rate; MBP, mean blood pressure; *Significant difference between groups, P < 0.05. Values are means ± SE. NC, normal control; HF, heart failure; HR, heart rate; MBP, mean blood pressure; *Significant difference between groups, P < 0.05.
